14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of VRNA
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Monday for Verona Pharma plc stock after losing 0%
(Updated on Apr 22, 2024)

Sell candidate since Apr 18, 2024 Loss -2.36% PDF

No changes to the price of Verona Pharma plc stock on the last trading day (Monday, 22nd Apr 2024). During the last trading day the stock fluctuated 3.75% from a day low at $15.48 to a day high of $16.06. The price has fallen in 7 of the last 10 days and is down by -6.87% for this period.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.56% during the next 3 months and, with a 90% probability hold a price between $13.01 and $15.36 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

VRNA Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, April 19, 2024, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Verona Pharma plc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $15.98 and $16.20. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while price remained unchanged. This may be an early warning, but it may also not. We still recommend that you pay attention over the next couple of days.

Support, Risk & Stop-loss for Verona Pharma plc stock

Verona Pharma plc finds support from accumulated volume at $15.65 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved $0.580 (3.75%) between high and low. For the last week, the stock has had daily average volatility of 3.77%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (VRNA) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect Verona Pharma plc to open at $15.75, and during the day (based on 14 day Average True Range), to move between $15.05 and $16.39, which gives a possible trading interval of +/-$0.667 (+/-4.24%) up or down from last closing price. If Verona Pharma plc takes out the full calculated possible swing range there will be an estimated 8.48% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $15.65 (0.45%) than the resistance at $15.91 (1.21%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Verona Pharma plc stock A Buy?

Verona Pharma plc holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -1.897 Sell Candidate Unchanged

Predicted Opening Price for Verona Pharma plc of Tuesday, April 23, 2024

Fair opening price April 23, 2024 Current price
$15.75 ( 0.212%) $15.72

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for VRNA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 16.33 3.90 %
R2 16.11 2.49 %
R1 15.97 1.62 %
Current price: 15.72
Support S1 15.53 -1.20 %
S2 15.39 -2.07 %
S3 15.17 -3.48 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 16.96 7.89 %
R2 16.75 6.55 %
R1 15.91 1.21 %
Current price 15.72
Support S1 15.65 -0.445%
S2 15.54 -1.15%
S3 15.30 -2.67%

FAQ

What is the symbol for Verona Pharma plc Stock and on which exchange is it traded?
The symbol for Verona Pharma plc is VRNA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Verona Pharma plc Stock?
Verona Pharma plc holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Verona Pharma plc Stock?
Verona Pharma plc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Verona Pharma plc Stock.

What's the current price of Verona Pharma plc Stock?
As of the end of day on the Apr 22, 2024, the price of an Verona Pharma plc (VRNA) share was $15.72.

What is the 52-week high and low for Verona Pharma plc Stock?
The 52-week high for Verona Pharma plc Stock is $23.81 and the 52-week low is $11.83.

What is the market capitalization of Verona Pharma plc Stock?
As of the Apr 22, 2024, the market capitalization of Verona Pharma plc is 1.265B.

When is the next earnings date for Verona Pharma plc?
The upcoming earnings date for Verona Pharma plc is May 14, 2024.
Click to get the best stock tips daily for free!

About Verona Pharma plc

Verona Pharma plc Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ... VRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT